Viewpoint MT and RadioMedix secure a second SBIR NCI grant for image guided therapy for metastatic melanoma
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA
RadioMedix initiates the first Ga-68 PSMA (ProstaMedix™) clinical trial for diagnosis and management of prostate cancer in U.S.
RadioMedix -ViewPointMT collaboration featured on the cover of ACS Carbohydrate Newsletter
RadioMedix, Inc. Receives FDA Orphan Drug Designation for the 68Ga-DOTATATE (GalioMedix TM) for the management of the neuroendocrine tumors
RadioMedix Inc. granted exclusive distribution authorization for ITG 68Ge/68Ga generators, and ITG iQS® Ga-68 Fluidic Labelling Module in U.S.A.
RadioMedix signs collaborative agreement with Viewpoint Molecular Targeting, LLC of Iowa City IA
cGMP Suite Registered by the FDA Drug Establishment Registration Database
RadioMedix Inc. is a co-sponsor and collaborator on the two IND clinical trials
RadioMedix Inc. Featured in the Small Chem Biz (SCHB) published by the American Chemical Society
RadioMedix Receives $1.4 Million Second Tranche Investment from Texas Emerging Technology Fund
RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.
RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.